Cáceres William, González Samuel
San Juan Veterans Affairs Medical Center, 10 Calle Casia, San Juan, Puerto Rico 00921.
P R Health Sci J. 2003 Jun;22(2):149-51.
Recent studies have shown the possibility to treat cancer with drugs that affect the formation of new blood vessels instead of attacking directly the malignant cell. This relatively new field in the area of oncology on angiogenesis inhibition has expanded the therapeutic option for malignant diseases. We will discuss several antiangiogenesis drugs in clinical development and their mechanism of action. Some of these drugs include: angiostatin, metalloproteinase inhibitors, thalidomide, tamoxifen, interferons and others. The use of antiangiogenic agents, both in combination with other treatment modalities in the acute setting as well as long-term maintenance or prevention of cancer, is at present one of the better promises in the war against cancer.
最近的研究表明，使用影响新血管形成的药物而非直接攻击恶性细胞来治疗癌症是有可能的。肿瘤学领域中这个相对较新的血管生成抑制领域，已经扩展了恶性疾病的治疗选择。我们将讨论几种处于临床开发阶段的抗血管生成药物及其作用机制。其中一些药物包括：血管抑素、金属蛋白酶抑制剂、沙利度胺、他莫昔芬、干扰素等。目前，抗血管生成药物无论是在急性情况下与其他治疗方式联合使用，还是用于癌症的长期维持或预防，都是抗癌战争中较有前景的方法之一。
